The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

This invention provides antibodies directed against a highly specific and previously unrecognized marker for cancerous cells. In certain embodiments an isolated antibody or fragment thereof that specifically binds human placentally expressed ALPP and/or ALPPL2, but not ALPL and ALPI that are expressed outside the placenta is provided as well as immunoconjugates comprising such antibodies.

A marker that can set a particularly clear cutoff value for distinguishing between follicular thyroid cancer (FTC) and follicular adenoma (FA), which is difficult in conventional pathological diagnosis is provided. Also provided are a method and a kit for diagnosing the development of FTC in a subject, comprising detecting expression of FAM19A2 in a sample derived from the thyroid tissue of the subject

The disclosure provides antibodies that specifically bind human IDO and methods of use thereof. In some aspects, the disclosure is directed to methods of detecting IDO in a biological sample comprising contacting the biological sample with an antibody described herein.

This invention provides a set of biological markers that are useful for detecting cancer. This invention further provides methods of using those biological markers for the diagnosis, prognosis, or monitoring of cancer.

The present invention relates to antibodies that neutralize the ability of the LEFTY proteins to induce the growth of cancer cells and diagnostic and therapeutic methods involving the same.

The application relates to the technical field of antibody drugs and provided are a group of sequences encoding a specific single-domain antibody for TROP2 and the use thereof. The provided anti-TROP2 single-domain antibody can effectively bind to a TROP2 antigen, and provides a basis for research and development of drugs targeting TROP2, including a nuclide-drug conjugate, an antibody-drug conjugate, a multispecific antibody drug, etc.

This invention relates to methods for detecting the presence of genetic markers for transitional cell carcinoma of the bladder. Specifically, this invention relates to detection of expression of overexpressed and underexpressed genetic markers and calculation of ratios of expression of these markers. In additional aspects, the invention relates to polymerase chain reaction (PCR) based kits for carrying out these methods.

A method for determining colorectal cancer risk includes obtaining a blood sample of the subject, isolating serum or EDTA plasma from the blood sample, analyzing the serum or EDTA plasma to determine plasma levels of very long chain dicarboxylic acid (VLCDCA 28:4), comparing the determined plasmas level of VLCDCA 28:4 of the subject with a predetermined range of plasma levels of VLCDCA 28:4 of diagnosed subjects having colorectal cancer, and determining a colorectal cancer risk exists when the determined plasma level of VLCDCA 28:4 is within the predetermined range of plasma levels of VLCDCA.

It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by multiple myeloma tumor cells. The alkylphophocholine analogs are compounds having the formula: ##STR00001##
or salts thereof, wherein n is an integer from 12 to 24; and R.sub.2 is N.sup.+H.sub.3, N.sup.+H.sub.2X, N.sup.+HX.sub.2, or N.sup.+HX.sub.3, wherein each X is independently CH.sub.3 or C.sub.2H.sub.5. The compounds can be used to treat multiple myeloma or to detect multiple myeloma. In therapeutic treatment, R.sub.1 includes a radionuclide that locally delivers therapeutic dosages of radiation to the multiple myeloma tumors cells that preferentially take up the compound. In detection/imaging applications, R.sub.1 includes a detection moiety, such as a fluorophore or a radiolabel.